Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KHK | P50053 | 1/20 | 0.51 |
| ▸ | FPR2 | P25090 | 5/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17269947 | 0.82 | KHK (0.45) | KHKLMNAMAPTHDAC1 | |
| SCHEMBL20224882 | 0.81 | CYP1A2 (0.52) | KHKEPHX2ALDH1A1LMNAMEN1 | |
| SCHEMBL17269902 | 0.78 | TGM2 (0.47) | KHKALDH1A1RAB9AHDAC1 | |
| SCHEMBL27760911 | 0.77 | NPSR1 (0.56) | KHKALDH1A1MAPTRAB9AMEN1 | |
| SCHEMBL31058163 | 0.73 | KHK (0.43) | KHKHDAC1 | |
| SCHEMBL17269941 | 0.73 | GPR119 (0.54) | EPHX2ALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL11428101 | 0.73 | EPHX2 (0.52) | FPR2EPHX2ALDH1A1LMNANOX1 | |
| SCHEMBL11427972 | 0.73 | EPHX2 (0.52) | FPR2EPHX2ALDH1A1LMNANOX1 | |
| SCHEMBL13696944 | 0.71 | TDP1 (0.53) | ALDH1A1LMNAMAPTRAB9ANPC1 | |
| SCHEMBL25775264 | 0.71 | MAPT (0.53) | EPHX2ALDH1A1LMNAMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170037007-A1 | SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | X-RX, INC. | 2017-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037007-A1 | SUBSTITUTED N-(2-(AMINO)-2OXOETHYL)BENZAMIDE INHIBITORS OF AUTOTAXIN AND THEIR PREPARATION AND USE IN THE TREATMENT OF LPA-DEPENDENT OR LPA-MEDIATED DISEASES | ENPP2, LPAR2, LPCAT3 | KHK 4704/4885FPR2 155/4885EPHX2 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.